Some structural analogues of amphetamine are now important drugs of abuse in Thailand. The utility of the Roche Abuscreen ONLINE reagent amphetamine immunoassay test kit to detect these analogues was studied. The test showed high cross-reactivity to 3,4-methylenedioxyamphetamine (MDA), but low cross-reactivity to its parent drugs, 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyethylamphetamine (MDEA), as well as to methamphetamine and ethylamphetamine. Also observed in this study was a methamphetamine detection sensitivity enhancement effect of amphetamine, which is the active metabolite of methamphetamine. Correlation between the measured concentration values and the actual amount of these two drugs in the sample was, however, low. Thus, the test can be used to detect methamphetamine only when amphetamine is also present in the sample resulting from either co-administration or metabolism of methamphetamine.
Introduction
Drug abuse is an increasing problem worldwide. In Thailand, it has been recognized in several places, including prisons, hospitals, schools, farms, and among the working population in general. Amphetamine and methamphetamine are among the most frequently abused drugs worldwide because of their widespread availability and low cost (1) . d-Methamphetamine, d-amphetamine, and d,l-amphetamine have been the most commonly abused amphetamines for decades (2) . Emergence of chemical analogues of amphetamine and methamphetamine, so-called "designer drugs", has compounded the problem. The production and use of these analogues are for the expressed purpose of evading law enforcement efforts to control drug abuse and have allowed individuals to create, possess, and sell abusable drugs that are, because of the modifications, outside of the scope of the controlled substances act. Although the controlled substances act has been updated to cover these designer drugs, the practical problem of detecting these drugs is still a factor in crippling law enforcement efforts. It is particularly urgent that their identification become a routine procedure so as to deter the use of these new drug materials. Until this capability is achieved, they can still be used without effective interference from law enforcement agencies (3) .
The structure of amphetamine can be altered by substitution on the amine or on the benzene ring. These analogues are commonly abused because of their ability to produce euphoria, increased physical capacity, and an apparent decrease in the need for food and rest. Several amphetamine analogues have been seen on the illicit market with increasing frequency (4). Ethylamphetamine is the N-ethyl amine analogue of amphetamine. It is widely known as an anorectic agent, Apetinil | It is abused as an alternative to amphetamine as well (5). 3,4-Methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"), and 3,4-methylenedioxyethylamphetamine (MDEA, "Eve") are ring-substituted analogues of amphetamine.
Widespread use of MDMA began in the early 1980s before it became a controlled substance. MDEA is the newest recreational drug and was listed as a schedule I controlled substance not long ago. MDA, although a popular drug of abuse in its own right, is also a metabolite of MDMA and MDEA produced in vivo by the Ndealkylation of the parent structures. This occurs in the same manner that methamphetamine and ethylamphetamine undergo N-dealkylation to form its metabolite, amphetamine (6) . Testing for amphetamines in drug-testing programs is generally limited to amphetamine and/or methamphetamine. Therefore, an abuser who uses one of these designer drugs has little to fear from the existing drug-testing programs (3) .
Generally the first step in the detection of possible drug consumption in modern forensic toxicological analysis is the immunological screening of a urine sample. Immunological assays are popular because the methods are simple, are able to test many samples in a short time, are of acceptable reliability, and are reasonably cost-effective. Amphetamine immunoassays are also widely recognized as problematic because of the large number of false-positive screen results that are produced. The false-positive results are due to the many sympathomimetic amine drugs found in over-the-counter (non-prescription) medications, including diet aids and cold remedies. In the testing of urine, false positives may result from drugs such as pseudoephedrine, phentermine, and phenylpropanolamine that are structurally similar to amphetamine. These medications are regularly ingested in sufficient quantities to yield high enough concentrations in urine samples submitted for drugs-of-abuse testing and lead to cross-reaction with the screening assays. Their concentrations are sometimes high enough to give a detection signal over the new SAMSHA cutoff or over 1000 ng/mL, which, therefore, requires a laboratory to have a rigorous, properly validated confirmation assay to positively identify the drugs of interest (7) . To minimize the number of false-positive urine samples and reduce unnecessary expenditure of time and money in confirmatory testing, screening methods need to have a high specificity. Although there are currently new diagnostic test kits that show little or no cross-reactivity with other sympathomemitic amines, these new test kits are not available in some parts of the world. Or if imported, their costs would be very high. Immunological techniques that use antibodies with cross-reactivity toward amphetamine analogues, however, are particularly useful for drug screening when and where the positive results for the analogues are expected.
Roche Abuscreen ONLINE reagent kit for amphetamine is based on the kinetic interaction microparticles in solution (KIMS). It contains mouse amphetamine and methamphetamine monoclonal antibodies, which, however, cannot give a positive result if only methamphetamine is present in urine. It has been reported that methamphetamine in the presence of amphetamine enhanced the reaction and gave a response in the assay that was greater than the sum of their concentrations (8) . This study was undertaken to determine if, and to what extent, the newest amphetamine analogues, MDEA and ethylamphetamine, cross-react with Roche Abuscreen ONLINE amphetamine immunoassays. This knowledge will enable drugtesting laboratories to more accurately evaluate results from the assays. The enhancement effect of amphetamine on methamphetamine from this reagent kit was also studied. The influences of amphetamine concentrations and stereoisomers of methamphetamine were of particular concern. , TX) . Stock (100,000 ng/mL free-base equivalent) standards of drugs were prepared in methanol and stored in the freezer. These solutions were diluted in drug-free urine to the given concentrations. The ONLINE amphetamine reagent kits (Roche Diagnostic Systems, Inc., Somerville, N J) were partially sponsored by Roche Diagnostic Systems, Inc. (Bangkok, Thailand), and assays were performed with Cobas Mira analyzer (Roche Diagnostic Systems, Inc.) according to the manufacturer's directions. A calibration curve plot of absorbance units versus amphetamine concentration was generated for ONLINE using Roche Abuscreen Preciset (Roche Diagnostic Systems, Inc.) and contained data points corresponding to 0, 500, 1000, and 2000-ng/mL d-amphetamine standards. Another calibration curve was also prepared from dmethamphetamine standard solutions; 0, 500, 1000, and 2000 ng/mL.
Results
The calibration curves for ONLINE amphetamine reagent kit made by using Abuscreen ONLINE Preciset and d-methamphetamine standard solutions are shown in Figures 1 and 2 , respectively. Table I shows that concentrations of ethylamphetamine of up to 50,000 ng/mL did not give a positive result when d-amphetamine was used to make the calibration curve. At the cutoff of 1000 ng/mL, neither MDEA nor MDMA up to 50,000 ng/mL gave a positive result. MDA, which is a primary amine similar to amphetamine, however, showed a high cross-reactivity with this method. Also d,l-amphetamine showed high cross-reactivity with this system. In the absence of amphetamine, urine containing either d-methamphetamine or d,l-methamphetamine at the concentration up to 50,000 ng/mL did not give a positive result by this method. Table II shows the cross-reactivity of amphetamine analogues when the calibration curve was constructed using d-methamphetamine standards. With this calibration curve, ethylamphetamine and MDEA at the concentration of 12,500 ng/mL gave a reaction signal greater than the cutoff. Increased cross-reactivities were found in cases of MDMA and MDA. In spite of a greater capacity to detect other amphetamine analogues, over-detection was found in case of d-amphetamine from this modified method. Table III 
Discussion
From the manufacturer's instruction, the ONLINE amphetamine test should be calibrated against d-amphetamine even though the test contained monoclonal antibodies to both amphetamine and methamphetamine. Additionally, according to the manufacturer's insert, the test is not sensitive to methamphetamine. In this study, the calibration curve was made using dmethamphetamine standards so as to determine if the test could be made more sensitive to methamphetamine. The results show that the calibration curve for d-amphetamine (Figure 1 ) has a steeper slope than that using d-methamphetamine standards (Figure 2) . The discrimination between the standard of 500 ng/mL and the cutoff concentration (1000 ng/mL) is about 0.15 AU for the d-amphetamine calibration curve and about 0.02 AU from the d-methamphetamine calibration curve. Therefore, the d-amphetamine calibration curve will provide a more specific assay, that is, greater separation between positive and negative results. The calibration curve derived from using d-methamphetamine standards showed higher sensitivity to methamphetamine as well as to other amphetamine analogues (Table II) . However, this modified method caused over-detection for amphetamine. Where no confirmatory test is available, the modified method should not be used in order to avoid non-reasonable false-positive results.
Although amphetamine is a metabolite of methamphetamine, both drugs are sometimes co-administrated. In many actual cases of methamphetamine abuse, no trace amounts of amphetamine were observed in the urine sample (9, 10) . By this evidence, Roche Abuscreen ONLINE, which is specific to amphetamine, will likely give a false negative with urine samples from some methamphetamine abusers. It is known that methamphetamine is popular in the USA (11) , and amphetamine is popular in Europe (12) . However, no data have specifically shown whether amphetamine or methamphetamine is a commonly abused drug in Thailand. When the Roche Abuscreen ONLINE amphetamine reagent kit is chosen for amphetamine screening test, there may be a number of false-negative results from the presence of methamphetamine alone.
As mentioned previously, ONLINE assay contained two monoclonal antibodies for amphetamine and methamphetamine. However, the methamphetamine antibody in the absence of amphetamine had a very low response to methamphetamine. AS shown in Table III , in the presence of amphetamine, there was an enhanced response for methamphetamine in the sample. This enhancement effect in the presence of a combination of amphetamine and methamphetamine has also been reported in the Abbott assay for amphetamine (13, 14) . Baker and colleagues (15) have evaluated the Abuscreen ONLINE assay for amphetamines on the Hitachi 737. According to their results, the mixture of 500 ng/mL of d-methamphetamine and 200 ng/mL of d-amphetamine and the mixture of 500 ng/mL of d-methamphetamine and 500 ng/mL of d-amphetamine gave responses greater than the sum of the amphetamine and methamphetamine concentrations. The results in our study showed the response was greater than the sum of the amphetamine and methamphetamine concentrations but only at the low concentration range of d-methamphetamine. At high levels of methamphetamine, the responses were not greater, or even lower, than the sum of the amphetamine and methamphetamine concentrations existing in the urine. The lack of correlation between results and the actual concentrations of the mixtures may be the result of altered antibody-binding characteristics due to cooperative effects resulting from the combination of two drugs. The enhancement effect showed a stereoisomeric dependency effect that is more reactive to d-methamphetamine than to racemic (d,l-) form. The enhancement effect also depends on the relative concentrations of amphetamine and methamphetamine presenting in the sample. Because the Cobas Mira analyzer is designed to give only semiquantitative results, results higher than 2000 ng/mL cannot be specified and the differences between the actual amount and the detected amount cannot be defined.
As seen in the interference study, when Abuscreen Preciset (damphetamine) was used as a calibrator (Table I) , only MDA showed significant cross-reactivity. AS has been reported (4), substantial cross-reactivity was seen with MDA more frequently in amphetamine assays than in methamphetamine assays. The results indicated that a sample containing ethylamphetamine, MDMA, MDEA, or methamphetamine at a concentration of approximately 50,000 ng/mL or less did not test positive with the Roche Abuscreen ONLINE amphetamine assay. From the structural point of view, it can be concluded that compounds with substitution on the amine nitrogen showed substantially reduced cross-reactivity with amphetamine reagents. The addition of a methylenedioxy substituent does not significantly impede binding with the antibody. Thus, the test can be used to check for MDA. As seen in Table I , when used for checking MDA, it should be realized that the detected amphetamine concentration is not a true reflection of the concentration of MDA present in the sample. Because of the lack of substantial cross-reactivity to the other amphetamine analogues studied, use of this testing methodology is limited. The probability of getting a positive response from these amphetamine analogues is small. The use of two or more reagent systems will increase the capability of identifying amphetamine, methamphetamine, and their analogues in urine, particularly for cases in which use is suspected (4).
Ethylamphetamine and MDEA showed cross-reactivity when the d-methamphetamine calibration curve was used, but less than MDMA. Similar to the cases of MDA when calibrated with damphetamine, using cross-reactivity data, the results did not correlate with the actual drug concentrations in the samples. Increased response in cross-reactivity to all amphetamine analogues studied and over-detection of amphetamine found when dmethamphetamine was used as calibrator may be a result of lower capacity to discriminate between negative and positive results on the calibration curve.
The mean MDA concentration was 1600 mg/mL with range of values from 150 to 8600 ng/mL. There appears to be no clear relationship between the MDMA and its metabolite, MDA, concentrations (14) . It is likely that MDEA will be metabolized and excreted in a similar manner with methamphetamine and MDMA, which is mostly in unchanged form and small amounts of their active metabolite forms, amphetamine and MDA, respectively (16) . By these data, Roche Abuscreen ONLINE amphetamine reagent kit gave positive results from MDA concentrations of 3000 ng/mL or higher by the manufacturer's recommended method. Therefore, the urine of abusers, especially chronic and heavy users, can give a positive result with this method for a reasonable length of time. Because there are many factors that influence the final urinary excretion of a given substance, including the dose administered, interindividual variations in drug metabolism and body clearance, and sample collection time (17, 18) .
